Methylphenidate Teva

Methylphenidate, the active ingredient in Methylphenidate Teva, is a central nervous system stimulant presented as an oral formulation for oral use. It treats Attention Deficit Hyperactivity Disorder and narcolepsy in children and adults.

GNH USA supplies Methylphenidate Teva as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylphenidate acts on central nervous system pathways involved in attention and wakefulness. - Attention Deficit Hyperactivity Disorder (ADHD): improves focus, reduces hyperactivity and impulsivity. - Adult ADHD: enhances concentration and task completion in adult patients. - Narcolepsy: decreases excessive daytime sleepiness and cataplexy episodes.

Methylphenidate may cause a range of adverse reactions.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Nausea: feeling of sickness or urge to vomit. - Stomach pain: abdominal discomfort. - Weight loss: unintended reduction in body weight.

Serious or Rare Side Effects: - Cardiovascular events: chest pain, hypertension, or arrhythmias. - Psychosis: emergence of hallucinations or delusional thoughts. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Priapism: prolonged, painful erection. - Seizures: convulsive episodes. - Mood swings: sudden changes in emotional state.

Before initiating therapy, consider the following safety measures. - Assess cardiovascular status: obtain baseline blood pressure and heart rate. - Monitor growth in children: track height and weight regularly. - Avoid use in patients with known hypersensitivity to methylphenidate. - Use caution with concomitant MAO inhibitors: ensure appropriate washout period. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture.

Methylphenidate can interact with several drug classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: may amplify cardiovascular effects. - Antihypertensive agents: potential reduction in blood pressure control.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors: may increase methylphenidate plasma levels. - Alcohol: can enhance central nervous system depression. - Antacids: may affect gastrointestinal absorption of the drug.